A Propensity Score–matched Comparison of Micro-ultrasound–guided Transrectal and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion-guided Transperineal Prostate Biopsies for Detection of Clinically Significant Prostate Cancer

Autor: Andrea Piccolini, Pier Paolo Avolio, Cesare Saitta, Edoardo Beatrici, Stefano Moretto, Muhannad Aljoulani, Filippo Dagnino, Davide Maffei, Nicola Frego, Vittorio Fasulo, Marco Paciotti, Rodolfo Hurle, Alberto Saita, Massimo Lazzeri, Paolo Casale, Piergiuseppe Colombo, Miriam Cieri, Nicolò Maria Buffi, Giovanni Lughezzani
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: European Urology Open Science, Vol 69, Iss , Pp 7-12 (2024)
Druh dokumentu: article
ISSN: 2666-1683
DOI: 10.1016/j.euros.2024.08.013
Popis: Background and objective: High-resolution micro-ultrasound (microUS) is an advanced imaging tool. Our objective was to determine whether systematic microUS use for transrectal biopsy (TRBx) improves the detection rate for clinically significant prostate cancer (csPCa) in comparison to transperineal biopsy (TPBx) performed with magnetic resonance imaging (MRI)/conventional transrectal ultrasound (TRUS) fusion software. Methods: We retrospectively analyzed data for men who underwent prostate biopsies, including those on active surveillance (AS). TRBx was performed under microUS guidance, while MRI/TRUS fusion was consistently used to guide TPBx. Patients were matched according to propensity score matching (PSM). The primary endpoint was comparison of the csPCa detection rate with the two approaches. Secondary endpoints included predictors of csPCa (International Society of Urological Pathology grade group ≥2, assessed via multivariable logistic regression) and complication rates. Key findings and limitations: Overall, 1423 patients were enrolled. After applying PSM we identified an analytical cohort of 1094 men, 582 in the TRBx group and 512 in the TPBx group. There was no significant difference in the csPCa detection rate between the TRBx (45%) and TPBx (51%) groups (p = 0.07). Complications occurred in nine of 1094 patients (1%). On adjusted multivariable analysis, TPBx had a similar csPCa detection rate to TRBx (adjusted odds ratio [aOR] 1.26;p = 0.09). Predictors of csPCa detection were a positive family history (aOR 1.68; 95% confidence interval [CI] 1.20–2.35; p = 0.002); age (aOR 1.04, 95% CI 1.02–1.06; p
Databáze: Directory of Open Access Journals